GI Pancreatic - Metastatic

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

Localized

NeoAdjuvant

Adjuvant

No Trials Currently Available

IRB# 15304
Stand up to Cancer: Study of the Safety, Immunopharmacodynamics and Antitumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

IRB# 16609
AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

IRB# 17094
AM0010-302

Key

No Trials Currently Available - Open for Enrollment

In Development

Enrollment on Hold

IRB# 11256
OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

Localized

NeoAdjuvant

Adjuvant

No Trials Currently Available

IRB# 15304
Stand up to Cancer: Study of the Safety, Immunopharmacodynamics and Antitumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

IRB# 16609
AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

IRB# 17094
AM0010-302

Key

No Trials Currently Available - Open for Enrollment

In Development

Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

6/28/2017